Trial Profile
A follow-on, Two-year Open-label Extension Study of Ganaxolone as add-on Therapy in Adult Patients With Drug-resistant Partial-onset Seizures
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 16 Feb 2023
Price :
$35
*
At a glance
- Drugs Ganaxolone (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions
- Sponsors Marinus Pharmaceuticals
- 06 Jan 2017 Status changed from recruiting to discontinued as Ganaxolone missed its primary endpoint in the double-blind portion of the 1042-0603 study.
- 13 Aug 2015 New trial record